Swiss Cancer League

Neon One is now an Intuit QuickBooks Solution Provider, simplifying financial accountability for small to midsize nonprofits

Retrieved on: 
Mardi, octobre 3, 2023
Swiss Cancer League, Marketing, Intuit, Mid-Market, San Francisco, Financial management, QuickBooks, Neon, Management, Internet service provider

CHICAGO, Oct. 3, 2023 /PRNewswire/ -- Neon One, a connected nonprofit platform utilized by over 6,500 nonprofits, is joining the QuickBooks Solution Provider Program to redefine the generosity experience for small to midsize nonprofits.

Key Points: 
  • CHICAGO, Oct. 3, 2023 /PRNewswire/ -- Neon One, a connected nonprofit platform utilized by over 6,500 nonprofits, is joining the QuickBooks Solution Provider Program to redefine the generosity experience for small to midsize nonprofits.
  • Neon One is joining the QuickBooks Solution Provider Program to redefine the generosity experience for nonprofits.
  • This fortified alliance presents nonprofits with an all-encompassing product suite, meticulously designed to seamlessly connect marketing, revenue, and impact data.
  • Roney Branch, Director of Mid-Markets and Partner Sales for QuickBooks, added: "QuickBooks has always sought innovative ways to streamline financial processes.

Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

Retrieved on: 
Jeudi, mars 9, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Swiss Cancer League, MD, Virology, McGill University, University School, The Ottawa Hospital, Oklahoma State University College of Agricultural Sciences and Natural Resources, Jennerex, Journal, CD8, Therapy, Euronext Paris, University of Ottawa Faculty of Medicine, Ottawa Hospital Research Institute, Research, School, OHRI, Medical Research Council, Potyvirus, Publication, New York University Grossman School of Medicine, National university, Agriculture Network Information Center, Clinical, Biochemistry, University, LICR, CTL, Immunotherapy, University of Lausanne, OV, Faculty, Doctor of Philosophy, Medical Research Council (United Kingdom), Épalinges, Ludwig Cancer Research, McMaster University, Pharmaceutical industry, Science, Medicine, Biology, Cancer, Nature

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.

Key Points: 
  • Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.
  • “John and Pedro are world leaders in cancer immunotherapy, and will bring considerable expertise to Transgene,” said Hedi Ben Brahim, Transgene’s CEO.
  • He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics.
  • Pedro obtained his MD at the School of Medicine of the National University of Colombia in Bogota.